1) FDA approves new Bristol-Myers treatment for multiple myeloma – PharmaLive, 11/30/2015
The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer.
2) Amid takeover rumors, Baxalta opens new Kendall Square research center – STAT, 12/2/2015
A new technique for so-called gene editing that formed the basis of well-funded Cambridge startups like Editas Medicine and CRISPR Therapeutics may have another use: Turning off genes that cause a rare form of muscular dystrophy.
3) Takeda exec to climb Mt. Kilimanjaro alongside blood cancer patients– BBJ, 12/2/2015
A nine-day trek to the summit of the world’s tallest free-standing mountain is a feat for even the healthiest of athletes. Next month, a local biotech executive will attempt to do so as part of a team in which nearly a quarter of the climbers have cancer.
4) Everything You Need to Know About CRISPR Gene Editing’s Monster Year – MIT Technology Review, 12/1/2015
The last 12 months have been incredible ones for genetic engineering. That’s mostly due to a new technology called CRISPR—an easy, cheap, and very precise way to “edit” the DNA of living cells.
5) New law restores lost time for makers of some drugs – STAT, 11/30/2015
After nearly three years of controversy, President Obama has signed a law that resets approval dates for some medicines that contain controlled substances. The goal is to streamline the process used by the US Drug Enforcement Agency to place prescription drugs that are controlled substances on a list of medicines for which distribution is restricted.